Dinaciclib

N/A

Report date: 2026/01/06 18:01:04
NME

Base Information

Drug NameDinaciclib
Drug Alias Name地那西利DinaciclibumNSC-727135MK-7965PS-095760 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 5 inhibitorsCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 2 inhibitors +[5] 
TargetsCyclin-dependent kinase 1Cyclin-dependent kinase 5Cyclin-dependent kinase 9 +[5] 
Therapy Area/IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteMerck Sharp & Dohme LLC
Inactive CompaniesAbbvie Inc
Active IndicationsSkin MelanomaSolid tumoursTriple Negative Breast Neoplasms +[5] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsBreast Neoplasms, Male +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG